Legal and regulatory exposurenegative · 3 filings
“McMurry-Heath was selected to serve on our Board due to her significant policy, regulatory, commercial healthcare and advocacy experience.”10-K · Mar 5, 2026 ↗
Bioventus Inc.
BVS
Market read
Bioventus Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 0 directly disclosed connections are confirming.
Company-4.3% todayVolume comparison unavailable
Market group0 of 1 activePain Management Devices · unavailable
Disclosed network0 of 0 confirmingRelationship data unavailable
What would change this read
Watch this read- BVS's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if BVS's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 0 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- BVS's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods7
Price observations318
Usable filing statements113
Verified relationships0
Evidence supporting the case
- Operating margin changed +12.2 percentage points in the latest annual period.
- Net margin changed +10.3 percentage points in the latest annual period.
- Operating cash flow covered net income at 3.28x in the latest annual period.
Evidence challenging the case
- Latest annual revenue changed -0.9% year over year.
- Diluted shares increased 6.8% in the latest annual period.
- Restructuring and cost reductions has repeated adverse evidence across 3 filings.
Questions before a position
No credible peer-relative valuation comparison is available yet.
Longer-term price context
Price as of Sep 9, 2026
13.646m+54.0%12m+87.6%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$430.9M+34.2%$-0.15—
2022-12-31$512.1M+18.8%$-2.59+35.0%
2023-12-31$512.3M+0.0%$-2.49+2.0%
2024-12-31$573.3M+11.9%$-0.56+3.0%
2025-12-31$568.1M-0.9%$0.33+6.8%
What management says matters
Persistent and emerging business drivers
Restructuring and cost reductionsnegative · 3 filings
“The Company evaluated the Wound Business for impairment prior to its sale and recorded a $ 78,615 impairment within the consolidated statements of operations and comprehensive income (loss) during the year ended December 31, 2023 as a result of this evaluatio…”10-K · Mar 5, 2026 ↗
Capital investment and capacitynegative · 2 filings
“The decrease was driven by a $1.6 million increase in capital expenditures, primarily related to information technology assets and a $0.7 million working capital settlement associated with the sale of the Advanced Rehabilitation Business.”10-Q · Nov 4, 2025 ↗
Credit and interest ratesnegative · 2 filings
“These outflows were partially offset by $25.0 million in net borrowings under our revolving credit facilities during the period.”10-Q · Nov 4, 2025 ↗
Valuation discipline
Peer-relative valuation withheld
Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
13.21-4.3% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:35 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for BVS. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for BVS. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind BVS
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
BVS is currently a Leader in the organic co-movement group Pain Management Devices. This group is discovered from market behaviour rather than assigned from an industry taxonomy. No verified filing-linked names are available yet.
This group is retained as the last observed read for BVS; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.